CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, Inc., today announced that it has dosed the first subject in a Phase 1a clinical trial evaluating its product candidate AKB-4924 for the treatment of IBD. This novel, orally administered agent that stabilizes hypoxia inducible factor 1 alpha (HIF-1α), a cellular protein which plays a crucial role in the resolution of inflammation and maintenance of epithelial barrier integrity. In multiple in vivo preclinical models of IBD, AKB-4924 has been sho
Uncategorized